Characteristics of mixed hyperlipidemia cases in a population-based study: Results from the Mexican National Survey of Chronic Diseases;Características de los casos con dislipidemias mixtas en un estudio de población: Resultados de la Encuesta Nacional de Enfermedades Crónicas

Salud Publica de Mexico

Volumn 44, Issue 6, 2002, Pages 546-553

  Aguilar Salinas, Carlos A ^a,c   Rojas, Rosalba ^b   Gómez Pérez, Francisco J ^a   Valles, Victoria ^a   Franco, Aurora ^b   Olaiz, Gustavo ^b   Tapia Conyer, Roberto ^b   Sepúlveda, Jaime ^b   Rull, Juan A ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^c NONE   (Mexico)

Author keywords

Diabetes mellitus; Hyperlipoproteinemia type V; Hypertension; Metabolic syndrome; Mexico; Triglicerides

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 5; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MEXICO; PREVALENCE; RISK FACTOR;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; HYPERLIPIDEMIAS; MALE; MEXICO;

EID: 0036864425     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Austin M, Hokanson JE, Edwards K. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81(4A):7B-12B.
2. Kesäniemi YA. Serum triglycerides and clinical benefit in lipid lowering trials. Am J Cardiol 1998;81(4A):70B-73B.
3. Sundquist J, Winkleby MA, Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: An analysis of NHANES 1988-1994. Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 2001;49:109-116.
4. Gaw A. Evidence based approach for the management of mixed hyperlipidemia. Atherosclerosis 1998;137 Suppl:S97-S100.
5. Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinol Metab Clin North Am 1998;27:551-567.
6. Gómez-Pérez FJ, Aguilar-Salinas CA. Hiperlipoproteinemias primarias. En: Posadas C, ed. Dislipidemias y Ateroesclerosis. México, D.F.: Editorial Interamericana: McGraw-Hill, 1995: 87-104.
7. Assmannn G, Schulte H. Results and conclusions of the Prospective Cardiovascular Münster (PROCAM) Study. En: Assmann G, ed. Lipid Metabolism Disorders and Coronary Heart Disease. MMV Medizin Verlag 1993: 21-67.
8. Frost P, Havel R. Rationale for use of non high density lipoprotein cholesterol rather than low density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998;81(4A):26B-31B.
9. Sniderman AD, Vu H, Cianflone K. The effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apoB levels. Atherosclerosis 1991;89:109-116.
10. Jiang F, Gibson AP, Dusting GJ. Endothelial dysfunction induced by oxidized low-density lipoproteins in isolated mouse aorta: A comparison with apolipoprotein-E deficient mice. Eur J Pharmacol 2001;424:141-149.
11. Jong MC, Havekes LM. Insights into apolipoprotein C metabolism from transgenic and gene targeted mice. Int J Tissue React 2000;22:59-66.
12. McGillicuddy CJ, Carrier MJ, Weinberg PD. Distribution of lipid deposits around aortic branches of mice lacking LDL receptors and apolipoprotein E. Arterios Thromb Vasc Biol 2001;21:1220-1225.
13. Chadarevian R, Brucker E, Dejager S, Presberg P, Turpin G. Relationship between triglycerides and factor VIIc and PAI-1: Lack of threshold value. Thromb Res 1999;96:175-182.
14. Li XN, Grenett HE, Benza RL, Demissie S, Brown SL, Tabengwa EM et al. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Arterios Thromb Vasc Biol 1997;17:3215-3223.
15. Fanghanel-Salmón G, Sánchez-Reyes L, Arellano S, Valdés S, Chavira J, Rascón A. The prevalence of risk factors for coronary disease in workers of the Hospital General de Mexico. Salud Publica Mex 1997;39:427-432.
16. Posadas-Romero C, Tapia-Conyer R, Lerman-Garber I, Zamora-González J, Cardoso-Saldaña G, Salvatierra-Izaba B et al. Cholesterol levels and prevalence of hypercholesterolemia in a Mexican adult population. Atherosclerosis 1995;118:275-284.
17. Aguilar-Salinas CA, Olaiz G, Valles V, Ríos JM, Gómez-Pérez FJ, Rull JA et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nation wide survey. J Lipid Research 2001;42:1298-1307.
18. Bhopal R, Unwin N, White M, Yallop J, Walker L, Alberti KGGM et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: Cross sectional study. BMJ 1999;319:215-220.
19. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high cholesterol. JAMA 2001;285:2486-2497.
20. Ballantyne C, Grundy SM, Oberman A, Kreisberg R, Havel R, Frost P et al. Hyperlipidemia: Diagnostic and therapeutic perspectives. J Clin Endoc Metab 2000;85:2089-2112.
21. Havel RJ, Frost P. The role of non-high-density lipoprotein cholesterol in evaluation and treatment of lipid disorders. J Clin Endocrinol Metab 2001;85:2105-2108.
22. Matthews D, Hosler JP, Rudenski AS, Naylor BA, Treacher DF, Turner R. Homeostasis model assessment: Insulin resistance and B-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412-419.
23. Taniguchi A, Fukushima M, Sakai M, Kataoka K, Nagata I, Doi K et al. The role of body mass index and triglycerides levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin dependent diabetic patients. Metabolism 2000;49:1001-1005.
24. Ballantyne C, Olsson AG, Cook TJ, Mercuri M, Pedersen T, Kjekshus J. For the Scandinavian Simvastatin Survival Study (4S) Group. Influence of low high-density lipoprotein cholesterol and elevated triglycerides in coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-3051.
25. Ezenwaka CE, Offiah NV. Cardiovascular risk in obese and nonobese patients with type 2 diabetes in the west indies. J Biomed Sci 2001;8:314-320.
26. Rajmohan L, Deepa R, Mohan A, Mohan V. Association between isolated hypercholesterolemia, isolated hypertriglyceridemia and coronary artery disease in south Indian type 2 diabetic patients. Indian Heart J 2000;52:400-406.
27. Miller M. Triglyceride as a risk factor, epidemiology. Lipids 1999;34 Suppl:S267.
28. Yarnell JWG, Patterson CC, Sweetnam PM, Thomas HF, Bainton D, Elwood PC et al. Do total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart disease? Ten-year follow-up of Caerphilly and Speedwell Cohorts. Arterios Thromb Vasc Biol 2001;21:1340-1345.
29. Grundy SM, Chait A, Brunzell J. Familial combined hyperlipidemia workshop. Arteriosclerosis 1987;7:203-207.
30. Aguilar-Salinas CA, Vázquez-Chávez C, Gamboa-Marrufo R, García-Soto N, Ríos-González JJ, Holguin R et al. Prevalence of obesity, diabetes, hypertension and tobacco consumption in an urban adult Mexican population. Arch Med Res 2001;32:446-453.
31. Eckel R. Familial combined hyperlipidemia and insulin resistance. Distant relatives linked by intra-abdominal fat? Circulation 2001;21:469-470.